, Tracking Stock Market Picks
Enter Symbol:
Infinity Pharmaceuticals, Inc. (INFI) [hlAlert]

down 72.59 %

Infinity Pharmaceuticals, Inc. (INFI) rated Outperform by Wells Fargo

Posted on: Thursday,  May 9, 2013  8:25 AM ET by Wells Fargo

Wells Fargo rated Outperform Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) on 05/09/2013, when the stock price was $33.28. Since
then, Infinity Pharmaceuticals, Inc. has lost 72.60% as of 01/25/2016's recent price of $9.12.
If you would have followed this Wells Fargo's recommendation on INFI, you would have lost 72.59% of your investment in 991 days.

Infinity Pharmaceuticals, Inc. (IPI) has developed a pipeline of product candidates for multiple cancer indications. The Company?s lead product candidate, retaspimycin hydrochloride (IPI-504) is an intravenously-administered small molecule inhibitor of heat shock protein 90 (Hsp90). Hsp90 is a central component of the cellular chaperone system, which supports and stabilizes cancer-causing proteins, such as c-Kit, EGFR, and HER2, enabling multiple forms of cancer to thrive. Inhibition of the Hsp90 chaperone knocks out this critical source of support for cancer cells, leading to tumor growth inhibition and cancer cell death. In October 2008, the commenced an international Phase III registration study of IPI-504 in patients with refractory gastrointestinal stromal tumors (GIST), based on the activity and safety data from a Phase I trial reported during the year ended December 31, 2008.

The investment research content is provided by Wells Capital Management, a registered investment adviser and wholly owned subsidiary of Wells Fargo Bank, N.A. Our economists’ expertise on domestic markets, and national and global trends, is an important resource to the firm. Wells Capital Management economists are known for their thoughts on investment strategy, macro-economic forecasts and other top-down analysis, and share their views on bonds, midcaps and liquidity management in their publications.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/9/2013 8:25 AM Buy
as of 12/13/2013
1 Week down  -13.31 %
1 Month down  -6.22 %
3 Months down  -37.93 %
1 YTD down  -61.05 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy